|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
|
US7226739B2
(en)
|
2001-03-02 |
2007-06-05 |
Isis Pharmaceuticals, Inc |
Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
|
|
US20030027135A1
(en)
|
2001-03-02 |
2003-02-06 |
Ecker David J. |
Method for rapid detection and identification of bioagents
|
|
US7666588B2
(en)
|
2001-03-02 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
|
|
US20040121309A1
(en)
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
|
|
US7718354B2
(en)
|
2001-03-02 |
2010-05-18 |
Ibis Biosciences, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
|
US7217510B2
(en)
|
2001-06-26 |
2007-05-15 |
Isis Pharmaceuticals, Inc. |
Methods for providing bacterial bioagent characterizing information
|
|
US8073627B2
(en)
|
2001-06-26 |
2011-12-06 |
Ibis Biosciences, Inc. |
System for indentification of pathogens
|
|
EP2213737B1
(en)
|
2002-02-01 |
2012-11-07 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
|
US7176002B2
(en)
*
|
2002-05-16 |
2007-02-13 |
Applera Corporation |
Universal-tagged oligonucleotide primers and methods of use
|
|
AU2003276666A1
(en)
*
|
2002-06-12 |
2003-12-31 |
Ambion, Inc. |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
|
US20060147924A1
(en)
*
|
2002-09-11 |
2006-07-06 |
Ramsing Neils B |
Population of nucleic acids including a subpopulation of lna oligomers
|
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
JP2006516193A
(ja)
|
2002-12-06 |
2006-06-29 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ヒトおよび動物における病原体の迅速な同定方法
|
|
US8046171B2
(en)
|
2003-04-18 |
2011-10-25 |
Ibis Biosciences, Inc. |
Methods and apparatus for genetic evaluation
|
|
US8057993B2
(en)
|
2003-04-26 |
2011-11-15 |
Ibis Biosciences, Inc. |
Methods for identification of coronaviruses
|
|
US7964343B2
(en)
|
2003-05-13 |
2011-06-21 |
Ibis Biosciences, Inc. |
Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
|
US8158354B2
(en)
|
2003-05-13 |
2012-04-17 |
Ibis Biosciences, Inc. |
Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
|
US20050089889A1
(en)
*
|
2003-06-20 |
2005-04-28 |
Ramsing Niels B. |
Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
|
|
US20070269803A1
(en)
*
|
2003-06-26 |
2007-11-22 |
Khalil Arar |
Fluorogenic Nucleic Acid Probes Including Lna for Methods to Detect and/or Quantify Nucleic Acid Analytes
|
|
US7956175B2
(en)
|
2003-09-11 |
2011-06-07 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
|
US8546082B2
(en)
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
|
US7480382B2
(en)
*
|
2003-09-30 |
2009-01-20 |
Microsoft Corporation |
Image file container
|
|
US7666592B2
(en)
|
2004-02-18 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for concurrent identification and quantification of an unknown bioagent
|
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
US8192937B2
(en)
|
2004-04-07 |
2012-06-05 |
Exiqon A/S |
Methods for quantification of microRNAs and small interfering RNAs
|
|
EP2458619B1
(en)
|
2004-05-24 |
2017-08-02 |
Ibis Biosciences, Inc. |
Mass spectrometry with selective ion filtration by digital thresholding
|
|
US20050266411A1
(en)
|
2004-05-25 |
2005-12-01 |
Hofstadler Steven A |
Methods for rapid forensic analysis of mitochondrial DNA
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
DE102004034343B4
(de)
*
|
2004-07-10 |
2007-08-30 |
Olfert Landt |
Verfahren zum Nachweis von Spuren genomischer Varianten mittels Nukleinsäure-Amplifikationsreaktionen
|
|
US7811753B2
(en)
|
2004-07-14 |
2010-10-12 |
Ibis Biosciences, Inc. |
Methods for repairing degraded DNA
|
|
WO2006135400A2
(en)
*
|
2004-08-24 |
2006-12-21 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification of recombinant organisms
|
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
US20060166238A1
(en)
*
|
2004-12-22 |
2006-07-27 |
Ramsing Niels B |
Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
|
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
WO2006069584A2
(en)
|
2004-12-29 |
2006-07-06 |
Exiqon A/S |
NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
|
|
US8071306B2
(en)
|
2005-01-25 |
2011-12-06 |
Merck Sharp & Dohme Corp. |
Methods for quantitating small RNA molecules
|
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
US8084207B2
(en)
|
2005-03-03 |
2011-12-27 |
Ibis Bioscience, Inc. |
Compositions for use in identification of papillomavirus
|
|
WO2006094238A2
(en)
|
2005-03-03 |
2006-09-08 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of adventitious viruses
|
|
US7838502B2
(en)
*
|
2005-05-06 |
2010-11-23 |
University Of Massachusetts Medical School |
Compositions and methods to modulate H. influenzae pathogenesis
|
|
US20100041738A1
(en)
*
|
2005-06-20 |
2010-02-18 |
Avaris Ab |
Hybridization-stabilizing construct
|
|
CA2616281C
(en)
|
2005-07-21 |
2014-04-22 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification and quantitation of mitochondrial dna variants
|
|
CA2617693A1
(en)
|
2005-08-17 |
2007-02-22 |
Medexis S.A. |
Composition and method for determination of ck19 expression
|
|
US20070087336A1
(en)
*
|
2005-10-17 |
2007-04-19 |
Rangarajan Sampath |
Compositions for use in identification of influenza viruses
|
|
JP5030110B2
(ja)
*
|
2005-12-21 |
2012-09-19 |
サムスン エレクトロニクス カンパニー リミテッド |
バイオメモリディスクドライブ装置及びそれを用いた分析方法
|
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
６−修飾された二環式核酸類似体
|
|
CA2648132C
(en)
*
|
2006-04-03 |
2019-05-28 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
US8088582B2
(en)
*
|
2006-04-06 |
2012-01-03 |
Ibis Biosciences, Inc. |
Compositions for the use in identification of fungi
|
|
EP2023940B1
(en)
|
2006-05-05 |
2011-06-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
JP5420412B2
(ja)
|
2006-09-14 |
2014-02-19 |
アイビス バイオサイエンシズ インコーポレイティッド |
病原体の同定のための標的全ゲノム増幅方法
|
|
WO2008046911A2
(en)
|
2006-10-20 |
2008-04-24 |
Exiqon A/S |
Novel human micrornas associated with cancer
|
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
|
JP2010510807A
(ja)
*
|
2006-11-27 |
2010-04-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
高コレステロール血症を治療するための方法
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
EP3536788A1
(en)
|
2006-12-21 |
2019-09-11 |
QIAGEN GmbH |
Microrna target site blocking oligos and uses thereof
|
|
JP5680304B2
(ja)
|
2007-02-23 |
2015-03-04 |
アイビス バイオサイエンシズ インコーポレイティッド |
迅速な法医学的ｄｎａ分析法
|
|
US20080274458A1
(en)
*
|
2007-05-01 |
2008-11-06 |
Latham Gary J |
Nucleic acid quantitation methods
|
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
US9598724B2
(en)
|
2007-06-01 |
2017-03-21 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
|
EP2173760B2
(en)
|
2007-06-08 |
2015-11-04 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
|
CA2692579C
(en)
|
2007-07-05 |
2016-05-03 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
DK2548962T3
(en)
|
2007-09-19 |
2016-04-11 |
Applied Biosystems Llc |
Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
|
|
KR101110013B1
(ko)
*
|
2007-10-05 |
2012-02-29 |
(주)바이오니아 |
서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
|
|
US8546556B2
(en)
*
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
|
EP2229457A4
(en)
|
2007-12-14 |
2011-01-26 |
Minitube America Inc |
SEX-SPECIFIC SEPARATION OF SPERM AND EMBRYOES
|
|
WO2009100320A2
(en)
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
|
DK2285819T3
(da)
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
|
US8148163B2
(en)
|
2008-09-16 |
2012-04-03 |
Ibis Biosciences, Inc. |
Sample processing units, systems, and related methods
|
|
WO2010033599A2
(en)
|
2008-09-16 |
2010-03-25 |
Ibis Biosciences, Inc. |
Mixing cartridges, mixing stations, and related kits, systems, and methods
|
|
EP2344893B1
(en)
|
2008-09-16 |
2014-10-15 |
Ibis Biosciences, Inc. |
Microplate handling systems and methods
|
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
WO2010040112A2
(en)
*
|
2008-10-03 |
2010-04-08 |
Curna, Inc. |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
ES2600781T3
(es)
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
|
CN102361985B
(zh)
|
2008-12-04 |
2017-06-20 |
库尔纳公司 |
通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
|
|
RU2620970C2
(ru)
|
2008-12-04 |
2017-05-30 |
КьюРНА,Инк., |
Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
|
|
WO2010080493A2
(en)
*
|
2008-12-18 |
2010-07-15 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention |
Real time polymerase chain reaction detection of legionella pneumophila and differentiation form other legionella species
|
|
AU2010207826B2
(en)
|
2009-02-02 |
2013-10-03 |
Qiagen Gmbh |
Method for quantification of small RNA species
|
|
EP2396803A4
(en)
|
2009-02-12 |
2016-10-26 |
Ibis Biosciences Inc |
IONIZATION PROBE ASSEMBLIES
|
|
WO2010093904A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
KR101805199B1
(ko)
*
|
2009-02-12 |
2017-12-05 |
큐알엔에이, 인크. |
신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ) 관련된 질환의 치료
|
|
EP2408919B1
(en)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
EP3249053A1
(en)
|
2009-03-27 |
2017-11-29 |
Life Technologies Corporation |
Methods, compositions, and kits for detecting allelic variants
|
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
|
ES2618572T3
(es)
|
2009-05-08 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd
|
|
WO2010135329A2
(en)
|
2009-05-18 |
2010-11-25 |
Curna, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
|
WO2010135692A2
(en)
|
2009-05-22 |
2010-11-25 |
Asuragen, Inc. |
Mirna biomarkers of prostate disease
|
|
KR101704988B1
(ko)
|
2009-05-28 |
2017-02-08 |
큐알엔에이, 인크. |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
|
|
ES2804764T3
(es)
|
2009-06-01 |
2021-02-09 |
Halo Bio Rnai Therapeutics Inc |
Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
|
|
ES2629339T3
(es)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
|
|
CA2765700C
(en)
|
2009-06-16 |
2021-01-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
|
EP2290102A1
(en)
|
2009-07-08 |
2011-03-02 |
Administración General De La Communidad Autónoma De Euskadi |
Methods for the diagnosis of multiple sclerosis based on its microRNA expression profiling
|
|
US9194877B2
(en)
|
2009-07-17 |
2015-11-24 |
Ibis Biosciences, Inc. |
Systems for bioagent indentification
|
|
US8950604B2
(en)
|
2009-07-17 |
2015-02-10 |
Ibis Biosciences, Inc. |
Lift and mount apparatus
|
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
ES2585360T3
(es)
|
2009-08-05 |
2016-10-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
|
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
ES2599986T3
(es)
|
2009-08-11 |
2017-02-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
|
|
EP2789693B1
(en)
|
2009-08-13 |
2017-10-04 |
Life Technologies Corporation |
Amelogenin SNP on chromosome X
|
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
|
EP2470657B1
(en)
|
2009-08-25 |
2019-10-23 |
CuRNA, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
|
EP2470897A4
(en)
|
2009-08-28 |
2013-05-29 |
Asuragen Inc |
MICRO-RNA BIOMARKERS OF PULMONARY DISEASE
|
|
WO2011032034A2
(en)
|
2009-09-10 |
2011-03-17 |
University Of Idaho |
Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
|
|
DK2480669T3
(en)
|
2009-09-25 |
2018-02-12 |
Curna Inc |
TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
|
|
EP2488668B1
(en)
|
2009-10-15 |
2023-07-26 |
Life Technologies Corporation |
Novel human single nucleotide polymorphisms
|
|
ES2628739T3
(es)
|
2009-10-15 |
2017-08-03 |
Ibis Biosciences, Inc. |
Amplificación por desplazamiento múltiple
|
|
AU2010319314C1
(en)
|
2009-11-13 |
2016-09-01 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
CA2782366A1
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
|
NO2516648T3
(https=)
|
2009-12-23 |
2018-04-07 |
|
|
|
RU2619185C2
(ru)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
|
|
US8921334B2
(en)
|
2009-12-29 |
2014-12-30 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
|
|
US8962585B2
(en)
|
2009-12-29 |
2015-02-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
|
DK2519632T3
(en)
|
2009-12-31 |
2018-07-23 |
Curna Inc |
TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
|
|
DK2521784T3
(en)
|
2010-01-04 |
2018-03-12 |
Curna Inc |
TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
|
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
|
KR101854926B1
(ko)
|
2010-01-11 |
2018-05-04 |
큐알엔에이, 인크. |
성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
|
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
DK2529015T3
(en)
|
2010-01-25 |
2018-02-26 |
Curna Inc |
TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
|
|
RU2608496C2
(ru)
|
2010-02-22 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1
|
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
|
EP2545173A2
(en)
|
2010-03-12 |
2013-01-16 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
EP3210611B1
(en)
|
2010-03-12 |
2019-08-21 |
The Brigham and Women's Hospital, Inc. |
Methods of treating vascular inflammatory disorders
|
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
|
AU2011230496B2
(en)
|
2010-03-26 |
2015-09-17 |
Integrated Dna Technologies, Inc. |
Methods for enhancing nucleic acid hybridization
|
|
US8980856B2
(en)
|
2010-04-02 |
2015-03-17 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
|
|
KR101900962B1
(ko)
|
2010-04-09 |
2018-09-20 |
큐알엔에이, 인크. |
섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
|
|
US8980253B2
(en)
|
2010-04-26 |
2015-03-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
|
CA2797362C
(en)
|
2010-04-27 |
2020-12-08 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
|
WO2011139853A2
(en)
|
2010-04-28 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
|
CA2797393C
(en)
|
2010-04-29 |
2020-03-10 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
|
US9212390B2
(en)
|
2010-04-30 |
2015-12-15 |
Exiqon A/S |
In situ hybridization method and buffer
|
|
CN103140233B
(zh)
|
2010-05-03 |
2017-04-05 |
Atyr 医药公司 |
与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
|
US8961961B2
(en)
|
2010-05-03 |
2015-02-24 |
a Tyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
|
|
RU2018110642A
(ru)
|
2010-05-03 |
2019-02-27 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
|
CN103096912A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
JP6008844B2
(ja)
|
2010-05-04 |
2016-10-19 |
エータイアー ファーマ， インコーポレイテッド |
ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
ES2816898T3
(es)
|
2010-05-13 |
2021-04-06 |
Sarepta Therapeutics Inc |
Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
|
|
EP2568996B1
(en)
|
2010-05-14 |
2017-10-04 |
aTyr Pharma, Inc. |
Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
CN103096914B
(zh)
|
2010-05-17 |
2015-08-12 |
Atyr医药公司 |
与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
CA2799207C
(en)
|
2010-05-26 |
2019-03-26 |
Curna, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
JP5917497B2
(ja)
|
2010-05-26 |
2016-05-18 |
カッパーアールエヌエー，インコーポレイテッド |
メチオニンスルホキシドレダクターゼａ（ｍｓｒａ）に対する天然アンチセンス転写物の阻害によるｍｓｒａ関連疾患の治療
|
|
CA2800375C
(en)
|
2010-05-27 |
2021-03-09 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2011163499A2
(en)
|
2010-06-23 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
|
EP2593125B1
(en)
|
2010-07-12 |
2017-11-01 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
|
AU2011299233B2
(en)
|
2010-09-07 |
2016-09-15 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
|
WO2012040403A1
(en)
|
2010-09-21 |
2012-03-29 |
Life Technologies Corporation |
Se33 mutations impacting genotype concordance
|
|
ES2640755T3
(es)
|
2010-10-06 |
2017-11-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
|
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
|
EP3260540A1
(en)
|
2010-11-12 |
2017-12-27 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
ES2657590T3
(es)
|
2010-11-23 |
2018-03-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
|
|
EP2663323B1
(en)
|
2011-01-14 |
2017-08-16 |
The General Hospital Corporation |
Methods targeting mir-128 for regulating cholesterol/lipid metabolism
|
|
EP2718439B1
(en)
|
2011-06-09 |
2017-08-09 |
CuRNA, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
|
BR112013033488B8
(pt)
|
2011-06-27 |
2022-11-22 |
Eisai R&D Man Co Ltd |
Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit
|
|
EP2546358A1
(en)
|
2011-07-15 |
2013-01-16 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and reagents for efficient control of HIV progression
|
|
EP2732035A2
(en)
|
2011-07-15 |
2014-05-21 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
|
KR101991980B1
(ko)
|
2011-09-06 |
2019-06-21 |
큐알엔에이, 인크. |
소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
CA2851280C
(en)
|
2011-10-11 |
2021-05-18 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
|
EP2788487B1
(en)
|
2011-12-08 |
2018-04-04 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human lmna
|
|
JP2015502365A
(ja)
*
|
2011-12-12 |
2015-01-22 |
オンコイミューニン，インコーポレイティド |
オリゴヌクレオチドのイン−ビボ送達
|
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
EP3597741A1
(en)
|
2012-04-27 |
2020-01-22 |
Duke University |
Genetic correction of mutated genes
|
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
|
ES2434853B1
(es)
|
2012-06-12 |
2014-09-30 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii |
Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos
|
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US10086093B2
(en)
|
2013-02-28 |
2018-10-02 |
The General Hospital Corporation |
miRNA profiling compositions and methods of use
|
|
WO2014164874A2
(en)
|
2013-03-13 |
2014-10-09 |
Becton, Dickinson And Company |
Methods and compositions for modulation of amplification efficiency
|
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
ES2523016B1
(es)
|
2013-05-20 |
2015-09-09 |
3P Biopharmaceuticals |
Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
|
|
CA2951816A1
(en)
*
|
2013-06-12 |
2014-12-18 |
Oncoimmunin, Inc. |
Systemic in vivo delivery of oligonucleotides
|
|
DE102013011304A1
(de)
*
|
2013-07-02 |
2015-01-22 |
Technische Universität Dresden |
Verfahren und Anordnung zur Erfassung von Bindungsereignissen von Molekülen
|
|
JP6618910B2
(ja)
|
2013-09-05 |
2019-12-11 |
サレプタ セラピューティクス，インコーポレイテッド |
酸性α−グルコシダーゼにおけるアンチセンス誘導エクソン２包含
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
AU2014375224A1
(en)
|
2014-01-05 |
2016-07-28 |
Biomirna Holdings Ltd |
Lung cancer determinations using miRNA ratios
|
|
WO2015120382A1
(en)
|
2014-02-07 |
2015-08-13 |
The Johns Hopkins University |
Predicting response to epigenetic drug therapy
|
|
WO2015126523A1
(en)
*
|
2014-02-21 |
2015-08-27 |
Clontech Laboratories, Inc. |
Spin columns comprising poly(acid) membrane separation matrices, and methods of making and using the same
|
|
RS60707B1
(sr)
|
2014-04-01 |
2020-09-30 |
Biogen Ma Inc |
Kompozicije za modulaciju ekspresije sod-1
|
|
DK3137476T3
(da)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
Linker-modificerede oligomerforbindelser
|
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
US10301624B2
(en)
|
2014-06-25 |
2019-05-28 |
The General Hospital Corporation |
Targeting human satellite II (HSATII)
|
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
|
EP3221445B1
(en)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Compositions and methods related to hematologic recovery
|
|
WO2016094330A2
(en)
|
2014-12-08 |
2016-06-16 |
20/20 Genesystems, Inc |
Methods and machine learning systems for predicting the liklihood or risk of having cancer
|
|
WO2016092045A1
(en)
|
2014-12-11 |
2016-06-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting medically refractory acute severe colitis
|
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2016177774A1
(en)
|
2015-05-04 |
2016-11-10 |
Academisch Medisch Centrum |
Method of quantifying mirnas using normalization
|
|
US10849917B2
(en)
|
2015-06-01 |
2020-12-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type VII collagen
|
|
CA2990852A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
|
JP2018525037A
(ja)
|
2015-08-24 |
2018-09-06 |
ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド |
遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
EP3359685B1
(en)
|
2015-10-09 |
2026-01-28 |
University Of Southampton |
Modulation of gene expression for deregulated protein expression
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
EP4454637A3
(en)
|
2015-11-16 |
2025-01-08 |
Olix Pharmaceuticals, Inc. |
Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
|
|
EA201891317A3
(ru)
|
2015-11-30 |
2019-04-30 |
Дьюк Юниверсити |
Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
|
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
EP3933041B1
(en)
|
2015-12-14 |
2024-01-31 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant retardation
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
KR102825946B1
(ko)
|
2016-02-02 |
2025-06-27 |
올릭스 주식회사 |
IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
|
|
US11234996B2
(en)
|
2016-02-25 |
2022-02-01 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting SMOC2
|
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
CA3021267A1
(en)
|
2016-04-18 |
2017-10-26 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
CN109477109B
(zh)
|
2016-04-29 |
2022-09-23 |
萨勒普塔医疗公司 |
靶向人lmna的寡核苷酸类似物
|
|
US11472824B2
(en)
|
2016-05-24 |
2022-10-18 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
|
MA49775A
(fr)
|
2016-05-24 |
2020-06-10 |
Sarepta Therapeutics Inc |
Procédés de préparation d'oligomères morpholino de phosphorodiamidate
|
|
MA45183A
(fr)
|
2016-05-24 |
2019-04-10 |
Sarepta Therapeutics Inc |
Procédés de préparation d'oligomères morpholino de phosphorodiamidate
|
|
MA45362A
(fr)
|
2016-05-24 |
2019-04-10 |
Sarepta Therapeutics Inc |
Procédés de préparation d'oligomères morpholino de phosphorodiamidate
|
|
TWI737736B
(zh)
|
2016-05-24 |
2021-09-01 |
美商薩羅塔治療公司 |
製備磷醯二胺嗎啉代寡聚物之方法
|
|
EP3471781A4
(en)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF GYS1 EXPRESSION
|
|
TW201811807A
(zh)
|
2016-06-30 |
2018-04-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
WO2018017814A1
(en)
|
2016-07-20 |
2018-01-25 |
President And Fellows Of Harvard College |
Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
|
|
WO2018053142A2
(en)
|
2016-09-14 |
2018-03-22 |
President And Fellows Of Harvard College |
Methods and compositions for modulating erythropoiesis
|
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
WO2018112033A1
(en)
|
2016-12-13 |
2018-06-21 |
President And Fellows Of Harvard College |
Methods and compositions for targeting tumor-infiltrating tregs
|
|
SI3554554T1
(sl)
|
2016-12-19 |
2023-02-28 |
Sarepta Therapeutics, Inc. |
Oligomerni konjugati, ki preskakujejo ekson za mišično distrofijo
|
|
IL297528A
(en)
|
2016-12-19 |
2022-12-01 |
Sarepta Therapeutics Inc |
Exon-skipping oligomer conjugates for muscular dystrophy
|
|
SMT202200366T1
(it)
|
2016-12-19 |
2022-11-18 |
Sarepta Therapeutics Inc |
Coniugati di oligomeri per salto di esone per distrofia muscolare
|
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
|
EP3609521A4
(en)
|
2017-04-14 |
2021-06-16 |
University of Massachusetts |
TARGETING OF CELL TROPISM RECEPTORS TO INHIBIT INFECTION BY THE CYTOMEGALOVIRUS
|
|
CN110536694A
(zh)
|
2017-04-20 |
2019-12-03 |
Atyr 医药公司 |
用于治疗肺部炎症的组合物和方法
|
|
US11197884B2
(en)
|
2017-08-18 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
SG11202001590RA
(en)
|
2017-08-25 |
2020-03-30 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
WO2019067975A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
WO2019067979A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
|
WO2019144061A1
(en)
|
2018-01-19 |
2019-07-25 |
Duke University |
Genome engineering with crispr-cas systems in eukaryotes
|
|
WO2019178346A1
(en)
*
|
2018-03-14 |
2019-09-19 |
The Trustees Of The University Of Pennsylvania |
Enrichment of nucleic acids
|
|
MX2020009765A
(es)
*
|
2018-03-20 |
2021-01-08 |
Tokyo Inst Tech |
Oligonucleotido antisentido reducido en toxicidad.
|
|
US12060558B2
(en)
|
2018-05-04 |
2024-08-13 |
Stoke Therapeutics, Inc. |
Methods and compositions for treatment of cholesteryl ester storage disease
|
|
US12582702B2
(en)
|
2018-05-11 |
2026-03-24 |
University Of Massachusetts |
Methods for improving leptin sensitivity for the treatment of obesity and diabetes
|
|
US10758629B2
(en)
|
2018-05-29 |
2020-09-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
EP3806868A4
(en)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
|
|
CN110669839B
(zh)
*
|
2018-07-03 |
2022-04-15 |
北京福安华生物科技有限公司 |
一种检测egfr基因t790m突变的人工模拟分子信标与试剂盒
|
|
TW202020153A
(zh)
|
2018-07-27 |
2020-06-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
EP3843845B1
(en)
|
2018-08-29 |
2026-03-11 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
|
US11273137B2
(en)
|
2018-09-04 |
2022-03-15 |
Board Of Trustees Of Michigan State University |
Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
|
|
EP3846824B1
(en)
|
2018-09-07 |
2025-06-18 |
The General Hospital Corporation |
Compositions and methods for immune checkpoint inhibition
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
BR112021008967A2
(pt)
|
2018-11-15 |
2021-08-17 |
Ionis Pharmaceuticals, Inc. |
moduladores da expressão de irf5
|
|
MX2021006737A
(es)
|
2018-12-13 |
2021-09-23 |
Sarepta Therapeutics Inc |
Conjugados de oligómeros de salto de exones para distrofia muscular.
|
|
CN112654714B
(zh)
|
2018-12-17 |
2024-10-11 |
伊卢米纳剑桥有限公司 |
用于测序的引物寡核苷酸
|
|
TW202540426A
(zh)
|
2019-02-27 |
2025-10-16 |
美商Ionis製藥公司 |
Malat1表現之調節劑
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
CN114040799A
(zh)
|
2019-03-12 |
2022-02-11 |
哈佛大学校长及研究员协会 |
治疗癌症的方法和组合物
|
|
EP3719144A1
(en)
|
2019-04-05 |
2020-10-07 |
Fundación para la Investigación Biomédica del Hospital Universitario de la Paz (FIBHULP) |
Mir-151a-3p as an universal endogenous control for exosome cargo normalization
|
|
EP3955966A1
(en)
|
2019-04-18 |
2022-02-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
WO2020226960A1
(en)
|
2019-05-03 |
2020-11-12 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
US20220226269A1
(en)
|
2019-06-12 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
|
|
EP3999664A1
(en)
|
2019-07-19 |
2022-05-25 |
Fundación para la Investigación Biomédica del Hospital Universitario de la Paz (FIBHULP) |
Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (nsclc)
|
|
EP3956450B1
(en)
|
2019-07-26 |
2025-08-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
EP4013767A4
(en)
|
2019-08-15 |
2023-10-25 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
|
CN115485385A
(zh)
|
2020-03-04 |
2022-12-16 |
瑞泽恩制药公司 |
用于使肿瘤细胞对免疫疗法敏感的方法和组合物
|
|
BR112022022889A2
(pt)
|
2020-05-11 |
2023-04-04 |
Stoke Therapeutics Inc |
Oligômeros antissentido de opa1 para tratamento de condições e doenças
|
|
US20230285357A1
(en)
|
2020-05-27 |
2023-09-14 |
The Regents Of The University Of California |
Compositions and methods for transdifferentiating cells
|
|
WO2022056454A2
(en)
|
2020-09-14 |
2022-03-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating hpv-positive cancers
|
|
IL301306A
(en)
|
2020-09-16 |
2023-05-01 |
Harvard College |
Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
|
|
MX2024003690A
(es)
|
2021-09-30 |
2024-06-19 |
Sarepta Therapeutics Inc |
Oligonucleótidos antisentido que tienen una o más unidades abásicas.
|
|
JP2024539223A
(ja)
|
2021-10-22 |
2024-10-28 |
サレプタ セラピューティクス， インコーポレイテッド |
末梢ミエリンタンパク質２２関連疾患の処置のためのモルフォリノオリゴマー
|
|
EP4433592A1
(en)
|
2021-11-18 |
2024-09-25 |
Circularis Biotechnologies, Inc. |
Compositions and methods for production of circular nucleic acid molecules
|
|
EP4437106A2
(en)
|
2021-11-24 |
2024-10-02 |
Prime Medicine, Inc. |
Methods and compositions for inhibiting mismatch repair
|
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
IL318625A
(en)
|
2022-07-29 |
2025-03-01 |
Regeneron Pharma |
Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
|
|
US20260049309A1
(en)
|
2022-08-15 |
2026-02-19 |
Novo Nordisk A/S |
Regulation of activity of rnai molecules
|
|
TW202424186A
(zh)
|
2022-08-25 |
2024-06-16 |
美商生命編輯治療學公司 |
Rna引導核酸酶中介基因編輯用之具鎖核酸引導 rna之化學修飾
|
|
WO2024064237A2
(en)
|
2022-09-21 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
|
IL320016A
(en)
|
2022-11-04 |
2025-06-01 |
Regeneron Pharma |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
JP2024129413A
(ja)
*
|
2023-03-13 |
2024-09-27 |
Ｋｍバイオロジクス株式会社 |
Ｔ細胞受容体遺伝子再構成断片（ＴＲＥＣ）、Ｉｇκ鎖遺伝子再構成断片（ＫＲＥＣ）およびＳＭＮ１遺伝子の量を定量ＰＣＲにより同時に測定する方法およびそのための新規プライマー
|
|
US20250066776A1
(en)
|
2023-04-27 |
2025-02-27 |
Sarepta Therapeutics, Inc. |
Antisense oligomers for treatment of chronic kidney disease
|
|
WO2024233864A2
(en)
|
2023-05-10 |
2024-11-14 |
Dicerna Pharmaceuticals, Inc. |
Galnac-conjugated rnai oligonucleotides
|
|
WO2025038750A2
(en)
|
2023-08-14 |
2025-02-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
WO2025085810A2
(en)
|
2023-10-18 |
2025-04-24 |
Sarepta Therapeutics, Inc. |
Antisense oligomers for treatment of centronuclear myopathies
|